Plasmacytoid dendritic cells control homeostasis of megakaryopoiesis.

Plasmacytoid dendritic cells control homeostasis of megakaryopoiesis.

Publication date: Jul 10, 2024

Platelet homeostasis is essential for vascular integrity and immune defence. Although the process of platelet formation by fragmenting megakaryocytes (MKs; thrombopoiesis) has been extensively studied, the cellular and molecular mechanisms required to constantly replenish the pool of MKs by their progenitor cells (megakaryopoiesis) remains unclear. Here we use intravital imaging to track the cellular dynamics of megakaryopoiesis over days. We identify plasmacytoid dendritic cells (pDCs) as homeostatic sensors that monitor the bone marrow for apoptotic MKs and deliver IFNα to the MK niche triggering local on-demand proliferation and maturation of MK progenitors. This pDC-dependent feedback loop is crucial for MK and platelet homeostasis at steady state and under stress. pDCs are best known for their ability to function as vigilant detectors of viral infection. We show that virus-induced activation of pDCs interferes with their function as homeostatic sensors of megakaryopoiesis. Consequently, activation of pDCs by SARS-CoV-2 leads to excessive megakaryopoiesis. Together, we identify a pDC-dependent homeostatic circuit that involves innate immune sensing and demand-adapted release of inflammatory mediators to maintain homeostasis of the megakaryocytic lineage.

Open Access PDF

Concepts Keywords
Bone Cellular
Homeostatic Demand
Megakaryocytes Dendritic
Plasmacytoid Dependent
Viral Homeostasis
Homeostatic
Identify
Immune
Megakaryopoiesis
Mks
Pdc
Pdcs
Plasmacytoid
Platelet
Sensors

Semantics

Type Source Name
pathway REACTOME Platelet homeostasis
disease IDO process
disease MESH viral infection
drug DRUGBANK Coenzyme M
drug DRUGBANK Diflunisal
disease IDO blood
disease IDO production
disease IDO cell
disease MESH Infectious Diseases
disease IDO facility
disease VO USA
disease MESH hyperplasia
disease MESH inflammation
disease MESH infection
disease IDO intervention
disease VO volume
disease VO time
drug DRUGBANK Trestolone
disease MESH emergency
drug DRUGBANK Thrombopoietin
pathway KEGG Apoptosis
disease VO phagocyte
disease MESH thrombocytopenia
drug DRUGBANK D-Tryptophan
disease MESH COVID 19
disease VO dose
disease VO population
disease VO Viruses
disease MESH cancer
disease MESH death
disease VO Pla
disease VO macrophage
disease MESH diphtheria
disease MESH atherogenesis
disease MESH autoimmune diseases
disease MESH influenza
drug DRUGBANK L-Tyrosine
disease MESH autoimmunity
disease IDO host
drug DRUGBANK Somatostatin
drug DRUGBANK Lenomorelin
drug DRUGBANK Isoxaflutole
disease MESH hemorrhage
drug DRUGBANK Tretamine
drug DRUGBANK Medical air
disease IDO pathogen
drug DRUGBANK Water
drug DRUGBANK Isoflurane
disease VO intraperitoneal injection
drug DRUGBANK Midazolam
drug DRUGBANK Fentanyl
disease MESH narcosis
disease MESH non Hodgkin lymphoma
disease MESH lymphoma
disease VO protocol
drug DRUGBANK Formic Acid
drug DRUGBANK Edetic Acid
drug DRUGBANK Formaldehyde
disease VO manufacturer
drug DRUGBANK Hyaluronic acid
disease IDO assay
drug DRUGBANK Tamoxifen
disease VO injection
disease VO ANOVA
disease VO dead
disease VO gene

Original Article

(Visited 1 times, 1 visits today)